IL-34在多发性骨髓瘤溶骨性病变中的作用
本研究首次发现多发性骨髓瘤(MM)细胞表达IL-34,该细胞因子可促进破骨细胞形成并加重溶骨性病变;靶向Il34的小干扰RNA在体外损害破骨细胞形成、在体内减轻溶骨性病变,患者骨髓CD138+细胞IL-34表达水平高低不一,中和抗体可减少IL-34促进的人CD14+单核细胞破骨细胞形成。
要点
- MM细胞系MOPC315.BM表达IL-34,炎性细胞因子或骨髓基质细胞刺激可增强其表达。
- MM细胞来源IL-34促进小鼠骨髓细胞及人CD14+单核细胞体外破骨细胞形成。
- 靶向Il34的小干扰RNA体外损害破骨细胞形成、体内减轻溶骨性病变。
核心结论
- 本研究首次描述MM细胞表达IL-34,提示其可能增强溶骨,并提示IL-34可作为控制MM患者病理性破骨细胞生成的潜在治疗靶点。
研究设计与样本
- 研究采用小鼠MM细胞系MOPC315.BM、小鼠骨髓细胞体外实验、体内小干扰RNA靶向Il34实验以及MM患者骨髓穿刺标本分析。
主要发现
- IL-34在小鼠MM细胞系MOPC315.BM中表达,且炎性细胞因子刺激或骨髓基质细胞可增强其表达。
- MM细胞来源IL-34在体外促进小鼠骨髓细胞破骨细胞形成。
- 靶向Il34的小干扰RNA在体外损害破骨细胞形成,并在体内减轻溶骨性病变。
- MM患者骨髓穿刺CD138+细胞IL-34表达水平在患者间从高到弱到缺失不等。
- MM细胞来源IL-34促进人CD14+单核细胞破骨细胞形成,抗IL-34中和抗体可减少该形成。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a hematological malignancy that grows in multiple sites of the axial skeleton and causes debilitating osteolytic disease. Interleukin-34 (IL-34) is a newly discovered cytokine that acts as a ligand of colony-stimulating factor-1 (CSF-1) receptor and can replace CSF-1 for osteoclast differentiation. In this study, we identify IL-34 as an osteoclastogenic cytokine that accelerates osteolytic disease in MM. IL-34 was found to be expressed in the murine MM cell line MOPC315.BM, and the expression of IL-34 was enhanced by stimulation with proinflammatory cytokines or by bone marrow (BM) stromal cells. MM-cell-derived IL-34 promoted osteoclast formation from mouse BM cells in vitro. Targeting Il34 by specific small interfering RNA impaired osteoclast formation in vitro and attenuated osteolytic disease in vivo. In BM aspirates from MM patients, the expression levels of IL-34 in CD138+ populations vary among patients from high to weak to absent. MM cell-derived IL-34 promoted osteoclast formation from human CD14+ monocytes, which was reduced by a neutralizing antibody against IL-34. Taken together, this study describes for the first time the expression of IL-34 in MM cells, indicating that it may enhance osteolysis and suggesting IL-34 as a potential therapeutic target to control pathological osteoclastogenesis in MM patients.
引用
- Baghdadi M, Ishikawa K, Nakanishi S, et al. A role for IL-34 in osteolytic disease of multiple myeloma. Blood Adv. 2019. PMID: 30782613. doi:10.1182/bloodadvances.2018020008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。